Phase 1 Brain Cancer Trial, Recruiting NCT06431685 Sponsor: Sichuan University Condition: Brain Cancer
Back to Brain Cancer

Phase 1 Brain Cancer Trial, Recruiting

NCT06431685
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 75 years old
  • People who have been diagnosed with leptomeningeal metastasis (cancer that has spread to the fluid and membranes surrounding the brain and spinal cord), either confirmed through spinal fluid testing or through a combination of medical history, brain scans, symptoms, and spinal fluid results
  • People who have a confirmed diagnosis of lung cancer, established through tissue or cell testing combined with imaging, where standard treatments have not worked
  • People whose cancer outside the brain has been stable (not growing) during treatment
  • People who have been assessed by a radiation doctor as having no reasons preventing them from receiving brain and spinal radiation, and who agree to receive immunotherapy, lumbar puncture (spinal tap), chemotherapy injected into the spinal fluid, and radiotherapy
  • People whose doctors estimate they are likely to live at least 3 more months and who have a general health score of 3 or below on a standard scale (confirm with trial site)
  • People who agree to provide spinal fluid, blood, and tissue samples for testing
  • People whose major organs (heart, lungs, liver, kidneys, bone marrow, and immune system) are functioning adequately, with no serious abnormalities
  • People whose blood counts, kidney function, and liver function meet specific test result thresholds within one week before joining (confirm with trial site for exact values)
  • Women who are able to become pregnant and who test negative for pregnancy within 7 days before joining, are not breastfeeding, and agree to use contraception during the trial and for 6 months after it ends; men who agree to use contraception during the trial and for 6 months after it ends

Who may not be able to join:

  • People who have an active autoimmune disease or a history of autoimmune disease (where the immune system attacks the body)
  • People who have a weakened immune system, either from birth or due to a medical condition
  • People with heart symptoms or heart disease that is not well controlled
  • People with serious infections or serious ongoing health conditions, such as a bleeding stomach ulcer, bowel blockage, heart failure, kidney failure, or poorly controlled diabetes
  • People who have previously received a transplanted organ or bone marrow/stem cells from another person
  • People who have had another cancer (other than lung cancer) within the past 5 years
  • People who are allergic to any of the drugs used in the trial
  • People with uncontrolled epilepsy, significant loss of neurological function, severe nerve damage from previous treatment, uncontrolled psychiatric conditions, or other conditions that the trial doctor considers unsuitable for participation
  • Women who are pregnant or breastfeeding, or people who are able to have children but are unwilling to use effective contraception

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: You Lu, MD, West China Hospital

Phone: 18980601763

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Sichuan University
Registry
ClinicalTrials.gov
Start date
25 April 2024
Est. completion
28 March 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Clinical response rate; Incidence of treatment-related adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov